Time for a comeback of NSAIDs in proteinuric chronic kidney disease?

Netherlands Journal of Medicine

Volumn 68, Issue 12, 2010, Pages 400-407

  Vogt, L ^a,b   Laverman, G D ^b   Navis, G ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

COX 2 inhibitors; Kidney disease; Nephrotic syndrome; NSAID; Prostaglandins; Proteinuria; Renin angiotensin aldosterone system

Indexed keywords

CANDESARTAN; HYDROCHLOROTHIAZIDE; INDOMETACIN; LISINOPRIL; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; NONHUMAN; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THROMBOCYTE AGGREGATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; KIDNEY FAILURE, CHRONIC; PROSTAGLANDINS; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM;

EID: 78651499296     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Vogt L, Navis G, de Zeeuw D. Renoprotection: a matter of blood pressure reduction or agent-characteristics? J Am Soc Nephrol. 2002;13(Suppl 3):S202-7.
2. De Zeeuw D. Renal disease: a common and a silent killer. Nat Clin Pract Cardiovasc Med. 2008;5(Suppl 1):S27-35.
3. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982;307(11):652-9.
4. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998;339(20)1448-56.
5. Ruggenenti P, Perna A, Remuzzi G; GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int. 2003;63(6):2254-61.
6. De Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65(6):2309-20.
7. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensinconverting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139(4):244-52.
8. Hillege HL, Fidler V, Diercks GF et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106(14):1777-82.
9. Ordoñez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 1993;44(3):638-42.
10. Mahmoodi BK, ten Kate MK, Waanders F, et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation. 2008;117(2):224-30.
11. KDOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Guideline 9. http://www.kidney.org/professionals/KDOQI/guidelines_bp/guide_9.htm
12. Deegens JK, Steenbergen EJ, Wetzels JF. Review on diagnosis and treatment of focal segmental glomerulosclerosis. Neth J Med. 2008;66(1):3-12.
13. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-9.
14. Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol. 2008;19(5):999-1007.
15. Ruggenenti P, Perticucci E, Cravedi P et al. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol. 2008;19(6):1213-24.
16. Vogt L, Navis G, de Zeeuw D. Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy? J Am Soc Nephrol. 2005;16(Suppl. 1):S53-7.
17. Fieschi A, Bianchi B. Il fenilbutazone. Un farmaco attivo sulla albuminuria. Prog Med Napoli. 1995;9:257-63.
18. De Vries LA, ten Holt SP, van Daatselaar JJ, Mulder A, Borst JGG. Characteristic renal excretion patterns in response to physiological, pathological and pharmacological stimuli. Clin Chim Acta. 1960;5:915-37.
19. Arisz L, Donker AJM, Brentjens JRH, van der Hem GK. The effect of indomethacin on proteinuria and kidney function in the nephrotic syndrome. Acta Med Scand. 1976;199:122-5.
20. Donker AJM, Brentjens JRH, van der Hem GK, Arisz L. Treatment of the nephrotic syndrome with indomethacin. Nephron. 1978;22:374-81.
21. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982;307(11):652-9.
22. Vriesendorp R, Donker AJM, de Zeeuw D, de Jong PE, van der Hem GK, Brentjens JRH. Effects of nonsteroidal anti-inflammatory drugs on proteinuria. Am J Med. 1986;81(Suppl. 2B):84-94.
23. Vriesendorp R, de Zeeuw D, de Jong PE, Donker AJ, Pratt JJ, van der Hem GK. Reduction of urinary protein and prostaglandin E2 excretion in the nephrotic syndrome by non-steroidal anti-inflammatory drugs. Clin Nephrol. 1986;25(2):105-10.
24. Weir MR. Renal effects of nonselective NSAIDs and coxibs. Cleve Clin J Med. 2002;69(Suppl 1):SI53-8.
25. Vriesendorp R, Donker AJ, de Zeeuw D, de Jong PE, van der Hem GK. Antiproteinuric effect of naproxen and indomethacin. A double-blind crossover study. Am J Nephrol. 1985;5(4):236-42.
26. Mathiesen ER, Hommel E, Olsen UB, Parving HH. Elevated urinary prostaglandin excretion and the effect of indomethacin on renal function in incipient diabetic nephropathy. Diabet Med. 1988;5(2):145-9.
27. Hommel E, Mathiesen E, Arnold-Larsen S, Edsberg B, Olsen UB, Parving HH. Effects of indomethacin on kidney function in type 1 (insulin-dependent) diabetic patients with nephropathy. Diabetologia. 1987;30(2):78-81.
28. Vogt L, de Zeeuw D, Woittiez AJJ, Navis G. Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients. Nephrol Dial Transplant. 2009;24(4):1182-9.
29. Heeg JE, de Jong PE, Vriesendorp R, de Zeeuw D. Additive antiproteinuric effect of the NSAID indomethacin and the ACE inhibitor lisinopril. Am J Nephrol. 1990;10(Suppl. 1):94-7.
30. Lagrue G, Laurent J, Belghiti D. Renal survival in membranoproliferative glomerulonephritis (MPGN): role of long-term treatment with non-steroid anti-inflammatory drugs (NSAID). Int Urol Nephrol. 1988;20(6):669-77.
31. Pisoni R, Ruggenenti P, Sangalli F, Lepre MS, Remuzzi A, Remuzzi G. Effect of high dose ramipril with or without indomethacin on glomerular selectivity. Kidney Int. 2002;62(3):1010-9.
32. Toto RD, Anderson SA, Brown-Cartwright D, Kokko JP, Brater DC. Effects of acute and chronic dosing of NSAIDs in patients with renal insufficiency. Kidney Int. 1986;30(5):760-8.
33. Tarnow I, Michelson AD, Barnard MR, et al. Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. Platelets. 2009;20(7):513-9.
34. Hopper AH, Tindall H, Davies JA. Administration of aspirin-dipyridamole reduces proteinuria in diabetic nephropathy. Nephrol Dial Transplant. 1989;4(2):140-3.
35. Donadio JV Jr, Ilstrup DM, Holley KE, Romero JC. Platelet-inhibitor treatment of diabetic nephropathy: a 10-year prospective study. Mayo Clin Proc. 1988;63(1):3-15.
36. Harris RC, Breyer MD. Update on cyclooxygenase-2 inhibitors. Clin J Am Soc Nephrol. 2006;1(2):236-45.
37. Qian Q, Kassem KM, Beierwaltes WH, Harding P. PGE2 causes mesangial cell hypertrophy and decreases expression of cyclin D3. Nephron Physiol. 2009;113(2):7-14.
38. Cheng H, Fan X, Guan Y, Moeckel GW, Zent R, Harris RC. Distinct roles for basal and induced COX-2 in podocyte injury. J Am Soc Nephrol. 2009;20(9):1953-62.
39. Harding P, Glass WF 2nd, Scherer SD. COX-2 inhibition potentiates the antiproteinuric effect of enalapril in uninephrectomized SHR. Prostaglandins Leukot Essent Fatty Acids. 2003;68(1):17-25.
40. Sinsakul M, Sika M, Rodby R, et al. A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. Am J Kidney Dis. 2007;50(6):946-51.
41. Adams DH, Howie AJ, Michael J, McConkey B, Bacon PA, Adu D. Non-steroidal anti-inflammatory drugs and renal failure. Lancet. 1986;1(8472):57-60.
42. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343(21):1520-8.
43. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092-102.
44. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109(17):2068-73.
45. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 2000;160(6):777-84.
46. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004;363(9423):1751-6.
47. Chan CC, Reid CM, Aw TJ, Liew D, Haas SJ, Krum H. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens. 2009;27(12):2332-41.